Advertisement

Human Papillomavirus Infection: A Risk Factor for Oral and Oropharyngeal Cancers

  • Giuseppina CampisiEmail author
  • Vera Panzarella
Chapter
  • 138 Downloads
Part of the Textbooks in Contemporary Dentistry book series (TECD)

Abstract

A wide range of human papillomavirus (HPV) prevalence data is now available for head and neck squamous cell carcinomas (HNSCCs), especially for those cancers originating from the epithelial lining of the upper aero-digestive tract (UADT) (i.e., the pharynx, the larynx, and the oral cavity). There is strong evidence that supports HPV as an etiological cause of head and neck carcinogenesis particularly for distinct oropharyngeal subsites. A specific molecular, histopathological, clinical, and prognostic profile is intimately connected with HPV infection. While the role of HPV in oropharyngeal carcinogenesis is firmly acknowledged, its role in oral cancer is currently being debated. Several recent studies suggest the importance of correctly distinguishing HNSCCs by subsites, and utilizing more sensitive HPV-DNA detection techniques, in designing future studies. Defining the HPV status of the tumor aids in the correct management of patients with oropharyngeal cancers.

References

  1. 1.
    Groves IJ, Coleman N. Pathogenesis of human papillomavirus-associated mucosal disease. J Pathol. 2015;235(4):527–38.PubMedCrossRefGoogle Scholar
  2. 2.
    Forman D, de Martel C, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30 Suppl 5:12–23.CrossRefGoogle Scholar
  3. 3.
    El-Naggar AK, Chan JKC, et al. WHO classification of head and neck tumors. Lyon (France): IARC; 2017.Google Scholar
  4. 4.
    Taberna M, Mena M, et al. HPV-relatedness definitions for classifying HPV-related oropharyngeal cancer patient do impact on TNM classification and patients’ survival. PLoS One. 2018;13(4):e0194107.PubMedPubMedCentralCrossRefGoogle Scholar
  5. 5.
    Egawa N, Egawa K, et al. Human Papillomaviruses; epithelial tropisms, and the development of neoplasia. Viruses. 2015;7:3863–90.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Ndiaye C, Mena M, et al. HPV DNA, E6/E7 mRNA, and p16INK4a detection in head and neck cancers: a systematic review and meta-analysis. Lancet Oncol. 2014;15:1319e31.CrossRefGoogle Scholar
  7. 7.
    Campisi G, Panzarella V, et al. Human papillomavirus: its identikit and controversial role in oral oncogenesis, premalignant and malignant lesions (Review). Int J Oncol. 2007;30:813–23.PubMedGoogle Scholar
  8. 8.
    Graham S. The human papillomavirus replication cycle, and its links to cancer progression: a comprehensive review. Clin Sci. 2017;131:2201–21.PubMedCrossRefGoogle Scholar
  9. 9.
    Peh WL, Middleton K, et al. Life cycle heterogeneity in animal models of human papillomavirus-associated disease. J Virol. 2002;76:10411–6.CrossRefGoogle Scholar
  10. 10.
    Campisi G, Giovannelli L. Controversies surrounding human papilloma virus infection, head &neck vs oral cancer, implications for prophylaxis and treatment. Head Neck Oncol. 2009;1:8.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    D’Souza G, Agrawal Y, et al. Oral sexual behaviours associated with prevalent oral human papillomavirus infection. J Infect Dis. 2009;199(9):1263–9.PubMedPubMedCentralCrossRefGoogle Scholar
  12. 12.
    Syrjänen S, Rautava J, Syrjänen K. HPV in head and neck cancer-30 years of history. Recent Results Cancer Res. 2017;206:3–25.PubMedCrossRefGoogle Scholar
  13. 13.
    Durzynska J, Lesniewicz K, et al. Human papillomaviruses in epigenetic regulations. Mutat Res. 2017;772:36–50.CrossRefGoogle Scholar
  14. 14.
    Faraji F, Zaidi M. Molecular mechanisms of human papillomavirus-related carcinogenesis in head and neck cancer. Microbes Infect. 2017;19:464e475.CrossRefGoogle Scholar
  15. 15.
    Global Burden of Disease Cancer Collaboration, Fitzmaurice C, Allen C, Barber RM, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 32 cancer Groups, 1990 to 2015: a systematic analysis for the global burden of disease study. JAMA Oncol. 2017;3(4):524–48.PubMedCentralCrossRefPubMedGoogle Scholar
  16. 16.
    Haeggblom L, Ramqvista T. Time to change perspectives on HPV in oropharyngeal cancer. A systematic review of HPV prevalence per oropharyngeal sub-site the last 3 years. Papillomavirus Research. 2017;4:1–11.PubMedPubMedCentralCrossRefGoogle Scholar
  17. 17.
    Tanaka TI, Alawi F. Human papillomavirus and oropharyngeal cancer. Dent Clin N Am. 2018;62(1):111–20.PubMedCrossRefGoogle Scholar
  18. 18.
    Ang KK, Harris J, et al. Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med. 2010;363(1):24–35.PubMedPubMedCentralCrossRefGoogle Scholar
  19. 19.
    Ali Qureishi A, Mawby T, et al. Current and future techniques for human papilloma virus (HPV) testing in oropharyngeal squamous cell carcinoma. Eur Arch Otorhinolaryngol. 2017;274:2675–83.PubMedCrossRefGoogle Scholar
  20. 20.
    Robinson M. HPV testing of head and neck cancer in clinical practice. Recent Results Cancer Res. 2017;206:101–11.PubMedCrossRefGoogle Scholar
  21. 21.
    Donà MG, Spriano G, et al. Human papillomavirus infection and p16 overexpression in oropharyngeal squamous cell carcinoma: a case series from 2010 to 2014. Future Microbiol. 2015;10(8):1283–91.PubMedCrossRefGoogle Scholar
  22. 22.
    Wasylyk B, Abecassis J, Jung AC. Identification of clinically relevant HPV-related HNSCC: in p16 should we trust? Oral Oncol. 2013;49(10):e33–7.PubMedCrossRefGoogle Scholar
  23. 23.
    Pannone G, Rodolico V, et al. Evaluation of a combined triple method to detect causative HPV in oral and oropharyngeal squamous cell carcinomas: p16 Immunohistochemistry, Consensus PCR HPV-DNA, and In Situ Hybridization. Infect Agent Cancer. 2012;7:4.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Huang SH, O’Sullivan B. Overview of the 8th edition TNM classification for head and neck cancer. Curr Treat Options in Oncol. 2017;18:40.CrossRefGoogle Scholar
  25. 25.
    Panzarella V, Pizzo G, et al. Diagnostic delay in oral squamous cell carcinoma: the role of cognitive and psychological variables. Int J Oral Sci. 2014;6:39–45.PubMedCrossRefGoogle Scholar
  26. 26.
    Rivera C, Oliveira AK, et al. Prognostic biomarkers in oral squamous cell carcinoma: a systematic review. Oral Oncol. 2017;72:38–47.PubMedCrossRefGoogle Scholar
  27. 27.
    SyrjänenK SS, et al. Morphological and immunohistochemical evidence suggesting human papillomavirus (HPV) involvement in oral squamous cell carcinogenesis. Int J Oral Surg. 1983;12:418–24.CrossRefGoogle Scholar
  28. 28.
    Krüger M, Pabst AM, et al. The prevalence of human papilloma virus (HPV) infections in oral squamous cell carcinomas: a retrospective analysis of 88 patients and literature overview. J Craniomaxillofac Surg. 2014;42:1506–14.PubMedCrossRefGoogle Scholar
  29. 29.
    Shan JS, Dong Y. Human papillomavirus and oral squamous cell carcinoma: a review of HPV-positive oral squamous cell carcinoma and possible strategies for future. Curr Probl Cancer. 2017;41:323–7.CrossRefGoogle Scholar
  30. 30.
    Galvis MM, Jardim JF. Expression of cell cycle proteins according to HPV status in oral squamous cell carcinoma affecting young patients: a pilot study. Oral Surg Oral Med Oral Pathol Oral Radiol. 2018;125:317–25.CrossRefGoogle Scholar
  31. 31.
    Chen X, Zhao Y. Human papillomavirus infection in oral potentially malignant disorders and cancer. Arch Oral Biol. 2017;83:334–9.PubMedCrossRefGoogle Scholar
  32. 32.
    Syrjänen S, Termine N, et al. Oral HPV infection: current strategies for prevention and therapy. Curr Pharm Des. 2012;18(34):5452–69.PubMedCrossRefGoogle Scholar
  33. 33.
    Kreimer AR, Bhatia RK, et al. Oral human papillomavirus in healthy individuals: a systematic review of the literature. Sex Transm Dis. 2010;37(6):386–91.PubMedGoogle Scholar
  34. 34.
    Kreimer AR, Villa A, et al. The epidemiology of oral HPV infection among a multinational sample of healthy men. Cancer Epidemiol Biomarkers Prev. 2011;20(1):172–82.PubMedCrossRefGoogle Scholar
  35. 35.
    Syrjänen S, Lodi G, et al. Human papillomaviruses in oral carcinoma and oral potentially malignant disorders: a systematic review. Oral Dis. 2011;17(Suppl. 1):58–72.PubMedCrossRefGoogle Scholar
  36. 36.
    Hübbers CU, Akgül B. HPV and cancer of the oral cavity. Virulence. 2015;6(3):244–8.PubMedPubMedCentralCrossRefGoogle Scholar
  37. 37.
    KansyK TO, Freier K. The role of human papillomavirus in oral squamous cell carcinoma: myth and reality. Oral Maxillofac Surg. 2014;18:165–72.CrossRefGoogle Scholar
  38. 38.
    Feller L, Lemmer J. Oral leukoplakia as it relates to HPV infection: a review. Int J Dent. 2012;2012:540–61.CrossRefGoogle Scholar
  39. 39.
    Campisi G, Giovannelli L, et al. HPV DNA in clinically different variants of oral leukoplakia and lichen planus. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2004;98(6):705–11.PubMedCrossRefPubMedCentralGoogle Scholar
  40. 40.
    Szarka K, Tar I, et al. Progressive increase of human papillomavirus carriage rates in potentially malignant and malignant oral disorders with increasing malignant potential. Oral Microbiol Immunol. 2009;24(4):314–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Campisi G, Giovannelli L, et al. Proliferative verrucous vs conventional leukoplakia: no significantly increased risk of HPV infection. Oral Oncol. 2004;40(8):835–40.PubMedCrossRefGoogle Scholar
  42. 42.
    Pentenero M, Meleti M, et al. Oral proliferative verrucous leukoplakia: are there particular features for such an ambiguous entity? A systematic review. Br J Dermatol. 2014;170:1039–47.PubMedCrossRefGoogle Scholar
  43. 43.
    Bagan JV, Jimenez Y, et al. Lack of association between proliferative verrucous leukoplakia and human papillomavirus infection. J Oral Maxillofac Surg. 2007;65(1):46–9.PubMedCrossRefGoogle Scholar
  44. 44.
    Yang SW, Lee YS, et al. Human papillomavirus in oral leukoplakia is no prognostic indicator of malignant transformation. Cancer Epidemiol. 2009;33(2):118–22.PubMedCrossRefGoogle Scholar
  45. 45.
    Termine N, Panzarella V, et al. HPV in oral squamous cell carcinoma vs head and neck squamous cell carcinoma biopsies: a meta-analysis (1988–2007). Ann Oncol. 2008;19:1681–90.PubMedCrossRefGoogle Scholar
  46. 46.
    Castillo A, Koriyama C, et al. Human papillomavirus in upper digestive tract tumors from three countries. World J Gastroenterol. 2011;17(48):5295–304.PubMedPubMedCentralCrossRefGoogle Scholar
  47. 47.
    Harris SL, Thorne LB, et al. Association of p16(INK4a) overexpression with improved outcomes in young patients with squamous cell cancers of the oral tongue. Head Neck. 2011;33(11):1622–7.PubMedCrossRefGoogle Scholar
  48. 48.
    Ishibashi M, Kishino M, et al. The prevalence of human papillomavirus in oral premalignant lesions and squamous cell carcinoma in comparison to cervical lesions used as a positive control. Int J Clin Oncol Jpn Soc Clin Oncol. 2011;16(6):646–53.CrossRefGoogle Scholar
  49. 49.
    Angiero F, Gatta LB, et al. Frequency and role of HPV in the progression of epithelial dysplasia to oral cancer. Anticancer Res. 2010;30(9):3435–40.PubMedGoogle Scholar
  50. 50.
    Elango KJ, Suresh A, et al. Role of human papilloma virus in oral tongue squamous cell carcinoma. Asian Pac J Cancer Prev. 2011;12(4):889–96.PubMedGoogle Scholar
  51. 51.
    Reuschenbach M, Kansy K, et al. Lack of evidence of human papillomavirus-induced squamous cell carcinomas of the oral cavity in southern Germany. Oral Oncol. 2013;49:937–42.PubMedCrossRefGoogle Scholar
  52. 52.
    Lingen MW, Xiao W, Schmitt A, et al. Low etiologic fraction for high-risk human papillomavirus in oral cavity squamous cell carcinomas. Oral Oncol. 2013;49:1–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Kouvousi M, Xesfyngi D, et al. Prevalence of human papillomavirus in 45 Greek patients with oral cancer. JOncol. 2013;2013:756510.Google Scholar
  54. 54.
    Ribeiro KB, Levi JE, et al. Low human papillomavirus prevalence in head and neck cancer: results from two large case-control studies in high-incidence regions. Int J Epidemiol. 2011;40:489–502.PubMedCrossRefGoogle Scholar
  55. 55.
    Prue G, Lawler M, Baker P, Warnakulasuriya S. Human papillomavirus (HPV): making the case for ‘Immunisation for All’. Oral Dis. 2017;23(6):726–30.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2020

Authors and Affiliations

  1. 1.Department of Surgical, Oncological and Oral Sciences (DICHIRONS)University of PalermoPalermoItaly

Personalised recommendations